Gyre Therapeutics
GYRE
7.04
-0.04
-0.57%
Gyre Therapeutics
US · GYRE
#3470 by market cap
Listed 2006
7.04
-0.04
-0.57%
Live - 5344 symbols - heartbeat 271s ago
· 2026-10-08 04:06
Pre-market
7.04
0.00%
After-hours
7.04
0.00%
- Market cap
- 746.48M
- P/E (TTM)i
- -33.52
- P/Bi
- 6.92
- EPSi
- 0.02
- Div yieldi
- 0.00%
- 52W posi
- 40%
Reader sentiment
Are you bullish or bearish on GYRE?
Anonymous reader poll. Unscientific, not investment advice.
About Gyre Therapeutics
Gyre Therapeutics, Inc. operates as a biopharmaceutical company. It is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis). The firm operates through the BC and Gyre segments. The company was founded on March 7, 1997 and is headquartered in San Diego, CA.
- Founded
- 1997
- CEO
- Dr. Ying Luo, PhD
- Employees
- 625
- Headquarters
- San Diego, California, United States of America
- Fiscal year end
- 12-31
- Website
- gyretx.com
Company profile
- Exchange
- US
- Symbol
- GYRE
- Market-cap rank
- #3470
- Listing date
- 2006-04-12
- Market cap
- 746.48M
- Float cap
- 253.03M
- Shares out
- 106.03M
- Float shares
- 35.94M
Sectors & themes
Biotechnology
Fractional Shares JP
Quote time 2026-10-08 04:06:39 · For reference only, not investment advice and not tailored to your situation.